BMRN INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
03. November 2021 18:45 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between...
uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
08. April 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, April 08, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
14. Mai 2020 07:00 ET
|
uniQure Inc.
~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~ ~ New Non-Human Primate Data Demonstrate Feasibility of...
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
04. Februar 2020 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
03. September 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 03, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences
26. Juli 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
30. April 2018 12:00 ET
|
uniQure Inc.
New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 to be Featured in Oral Presentation LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 30, 2018 (GLOBE NEWSWIRE) --...